As the world awaits a COVID-19 vaccine, the next big advance in battling the pandemic could come from a class of biotech therapies widely used against cancer and other disorders - antibodies designed specifically to attack this new virus.
Rival drugmakers AbbVie Inc , Amgen Inc and Takeda Pharmaceuticals Inc on Monday said they have begun treating patients in a trial to quickly show whether a drug from each company can be repurposed and used against COVID-19, the disease caused by the novel coronavirus.
Two major drug companies will supply the U.S. government with 100 million doses of an experimental coronavirus vaccine, the Trump administration said on Friday, as the nation's top health agency predicted that fatalities would rise in the coming weeks.
Gilead Sciences Inc on Thursday posted worse-than-expected quarterly results, but raised its 2020 sales forecast to include revenue from its antiviral drug remdesivir, one of the only treatments shown to help COVID-19 patients.
Amgen Inc said on Tuesday second-quarter revenue rose 6% as higher sales of newer drugs, including recently added psoriasis treatment Otezla, offset declining sales of older medicines which were due in some cases to people staying home to avoid exposure to the new coronavirus.
July 28 Amgen Inc on Tuesday reported
second-quarter revenue rose 6% as higher sales of newer drugs,
including recently-added psoriasis treatment Otezla, offset
declining sales of older medicines.
The U.S. Department of Justice on Thursday said it will not stand in the way of efforts by companies, including Eli Lilly and Co and Amgen Inc, to share information to help scale up capacity to manufacture antibody treatments for COVID-19, the disease caused by the new coronavirus.
LOS ANGELES Two potential vaccines to protect against the novel coronavirus - one from Oxford University and AstraZeneca Plc and the other from China's CanSino Biologics - induced immune responses in healthy volunteers without causing dangerous side effects, according to studies published on Monday in The Lancet.